  We assess costs and efficiency of state-of-the-art high performance cloud
computing compared to a traditional on-premises compute cluster. Our use case
are atomistic simulations carried out with the GROMACS molecular dynamics (MD)
toolkit with a focus on alchemical protein-ligand binding free energy
calculations.
  We set up a compute cluster in the Amazon Web Services (AWS) cloud that
incorporates various different instances with Intel, AMD, and ARM CPUs, some
with GPU acceleration. Using representative biomolecular simulation systems we
benchmark how GROMACS performs on individual instances and across multiple
instances. Thereby we assess which instances deliver the highest performance
and which are the most cost-efficient ones for our use case.
  We find that, in terms of total costs including hardware, personnel, room,
energy and cooling, producing MD trajectories in the cloud can be as
cost-efficient as an on-premises cluster given that optimal cloud instances are
chosen. Further, we find that high-throughput ligand-screening for
protein-ligand binding affinity estimation can be accelerated dramatically by
using global cloud resources. For a ligand screening study consisting of 19,872
independent simulations, we used all hardware that was available in the cloud
at the time of the study. The computations scaled-up to reach peak performances
using more than 4,000 instances, 140,000 cores, and 3,000 GPUs simultaneously
around the globe. Our simulation ensemble finished in about two days in the
cloud, while weeks would be required to complete the task on a typical
on-premises cluster consisting of several hundred nodes. We demonstrate that
the costs of such and similar studies can be drastically reduced with a
checkpoint-restart protocol that allows to use cheap Spot pricing and by using
instance types with optimal cost-efficiency.
